Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.57 |
| ▸ | PARP1 | P09874 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | RECQL | P46063 | 1/20 | 0.57 |
| ▸ | BLM | P54132 | 1/20 | 0.57 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.51 |
| ▸ | F7 | P08709 | 1/20 | 0.47 |
| ▸ | F3 | P13726 | 1/20 | 0.47 |
| ▸ | SARM1 | Q6SZW1 | 1/20 | 0.47 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.47 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.47 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quinoline SCHEMBL2201840 | 0.91 | ALDH1A1 (0.74) | ALDH1A1CYP3A4PARP1POLBMAPT | |
| Quinoline SCHEMBL5272119 | 0.91 | ALDH1A1 (0.74) | ALDH1A1CYP3A4PARP1POLBMAPT | |
| 8-Aminoquinoline SCHEMBL28879412 | 0.87 | PARP1 (0.50) | ALDH1A1CYP3A4PARP1POLBMAPT | |
| Quinoline SCHEMBL29158803 | 0.87 | MEN1 (0.53) | ALDH1A1PARP1MAPTCYP2C19TDP1 | |
| Quinoline SCHEMBL29158789 | 0.87 | ALDH1A1 (0.53) | ALDH1A1CYP3A4PARP1POLBMAPT | |
| Quinoline SCHEMBL1287895 | 0.87 | ALDH1A1 (0.74) | ALDH1A1CYP3A4PARP1POLBMAPT | |
| Quinoline SCHEMBL5874527 | 0.85 | ALDH1A1 (0.65) | ALDH1A1CYP3A4MAPTTSHRTDP1 | |
| Quinoline SCHEMBL8930504 | 0.85 | ALDH1A1 (0.65) | ALDH1A1CYP3A4MAPTTSHRTDP1 | |
| Quinoxaline SCHEMBL11668022 | 0.85 | MAPT (0.67) | ALDH1A1CYP3A4PARP1POLBMAPT | |
| Quinoline SCHEMBL28970061 | 0.85 | ALDH1A1 (0.71) | ALDH1A1CYP3A4POLBMAPTTSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752186-A | A kind of preparation method of 2- benzyls -5- trifluoromethylbenzoic acids | 安徽古尔特科技有限公司 | 2018-11-06 | — | — | CN | claimed |
| CN-108485307-A | A kind of fluorescent dye, preparation method and applications for opening property with fluorescence | 浙江工业大学 | 2018-09-04 | — | — | CN | disclosed |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. | 2017-12-07 | — | — | US | disclosed |
| CN-107260726-A | Composition and method for treating nerve degenerative diseases | 考格尼申治疗股份有限公司 | 2017-10-20 | — | — | CN | disclosed |
| CN-107162972-A | The preparation method of the trimethylbenzoyl amine of N phenyl N [8] quinolyl 2,4,6 | 湖北工业大学 | 2017-09-15 | — | — | CN | disclosed |
| CN-106928231-A | The kinase inhibitor of the new EGFR wild types of one class and saltant type | 合肥中科普瑞昇生物医药科技有限公司 | 2017-07-07 | — | — | CN | disclosed |
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2014-12-25 | — | — | US | disclosed |
| CN-104053436-A | Compositions and methods for treating neurodegenerative diseases | COGNITION THERAPEUTICS INC | 2014-09-17 | — | — | CN | disclosed |
| EP-2747768-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | Cognition Therapeutics, Inc. (US) | 2014-07-02 | — | — | EP | disclosed |
| CN-103242315-A | Salt of quinoline benzamide derivative | SHANGHAI YIZHI MEDICAL TECH CO | 2013-08-14 | — | — | CN | disclosed |
| CN-103242315-A | Salt of quinoline benzamide derivative | SHANGHAI YIZHI MEDICAL TECH CO | 2013-08-14 | — | — | CN | disclosed |
| WO-2013029060-A2 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | COGNITION THERAPEUTICS, INC. (US) | 2013-02-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140378460-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | ALDH1A1 4387/4885CYP3A4 4754/4885PARP1 4775/4885 |
| US-20170349554-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASE | TMEM97, SLC18A2, SIGMAR1 | ALDH1A1 4387/4885CYP3A4 4754/4885PARP1 4775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.